RDD Blog » filed for approval

R&D Directions Insider

Archive for the ‘ filed for approval ’ Category

Dual-filing feat a rarity for little guy

Wednesday, February 17th, 2010

You may have read recently about a small biotech outfit in New Jersey having successfully submitted simultaneous regulatory filings in the United States and Europe for Luveniq, a new oral treatment for non-infectious uveitis, an inflammatory condition of the eye that can lead to blindness (see the release here). You ...

Posted in Uncategorized, clinical trials, filed for approval | No Comments »

Big stage for diabetes hopeful

Friday, August 28th, 2009

Recent regulatory setbacks aside, Takeda Pharmaceutical Co. is plowing full steam ahead on its quest to win approval for the companyâ€™s key type 2 diabetes drug alogliptin, another potential entrant into the suddenly competitive field of DPP-4 inhibitors. The Japanese drug giant said today that it received the â€œall-clearâ€ from FDA ...

Posted in CRO, Uncategorized, clinical trials, diabetes, filed for approval | No Comments »

Clumps key in Huntingtonâ€™s disease breakthrough

Friday, June 5th, 2009

Scientists have figured out the cause of brain damage and death in Huntingtonâ€™s disease patients that may lead to treatments to stop the disease. There is currently only one treatment that eases the symptoms of Huntingtonâ€™s, Xenazine, marketed and developed by H. Lundbeck. Although there are a handful of drugs ...

Posted in clinical trials, filed for approval | No Comments »

Prasugrel not pleasing

Wednesday, June 3rd, 2009

Since January 2008, FDA has been discussing the benefits over the risks of Eli Lillyâ€™s prasugrel. The drug prevents more heart attacks than Plavix, but causes more internal bleeding, according to a study conducted by Lilly. Consumer health advocates and Dr. Victor Serebruany, who worked on the early development of ...

Posted in filed for approval | No Comments »

©2012 UBM Canon